Christos Sotiriou

Service(s) : Laboratoire Heuson de recherche translationnelle en cancérologie mammaire, Clinique d'oncologie médicale

christos.sotiriou [at] bordet.be

Publications

Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and Challenges.

Auteurs : Wang X, Collet L, Rediti M, Debien V, De Caluwé A, Venet D, Romano E, Rothé F, Sotiriou C, Buisseret L
Année : 2023
Journal : J Clin Med

Correction to: Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub‑analysis of the ALTTO trial (BIG 2‑06; NCCTG (Alliance) N063D).

Auteurs : Pondé N, Agbor-Tarh D, Dal Lago L, Korde LA, Hilbers F, Jackisch C, Werner O, Gelber Rd, Jatoi A, Dueck AC, Moreno-Aspitia A, Sotiriou C, de Azambuja E, Piccart M
Année : 2022
Journal : Breast Cancer Res Treat

Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer.

Auteurs : Chang CA, Jen J, Jiang S, Sayad A, Mer AS, Brown KR, Nixon AML, Dhabaria A, Tang KH, Venet D, Sotiriou C, Deng J, Wong KK, Adams S, Meyn P, Heguy A, Skok JA, Tsirigos A, Ueberheide B, Moffat J, Singh A, Haibe-Kains B, Khodadadi-Jamayran A, Neel BG
Année : 2022
Journal : Cancer Discov

Incorporation of TILs in daily breast cancer care: how much evidence can we bear?

Auteurs : Lænkholm AV, Callagy G, Balancin M, Bartlett JMS, Sotiriou C, Marchio C, Kok M, Dos Anjos CH, Salgado R
Année : 2022
Journal : Virchows Arch

Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer.

Auteurs : Loi S, Salgado R, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, Gray R, Munzone E, Drubay D, Lemonnier J, Sotiriou C, Kellokumpu-Lehtinen PL, Vingiani A, Gray K, André F, Denkert C, Piccart-Gebhart M, Roblin E, Michiels S
Année : 2022
Journal : NPJ Breast Cancer

Plus de publications »

Christos Sotiriou

Suivez-nous!

Le nouvel Institut Jules Bordet.

Languages

Contact